Hypoxic cancer cells preferentially release miR-210 loaded exosomes (91), which can work on other normoxic cancer cells within the TME, and promote VEGFA expression and angiogenesis by targeting vascularization modulators such as Ephrin A3 (EFNA3) and protein tyrosine phosphatase non-receptor type 1 (PTP1B) (92). The gene discussed is EFNA3; the disease is cancer.